SCHEMBL5541837

SCHEMBL5541837

Cc1cc2scnc2cc1[O]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.41
RAB9A P51151 7/20 0.41
KDM4E B2RXH2 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
HKDC1 Q2TB90 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 5/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38
STIM1 Q13586 1/20 0.36
ORAI1 Q96D31 1/20 0.36
DYRK1A Q13627 1/20 0.35
PKM P14618 1/20 0.35
TGFBR1 P36897 4/20 0.34
BMPR1A P36894 1/20 0.34
SMAD2 Q15796 1/20 0.34
MAPT P10636 2/20 0.33
TAS1R3 Q7RTX0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4048510 0.83 GAA (0.45) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL30093444 0.83 GAA (0.45) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL2999828 0.76 TERT (0.45) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL720130 0.76 ALDH1A1 (0.38) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL4055332 0.76 NPC1 (0.41) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL30089784 0.76 ALDH1A1 (0.38) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL4052274 0.76 RIPK2 (0.39) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL12121770 0.76 TGFBR1 (0.44) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL4296143 0.75 ALDH1A1 (0.52) NPC1RAB9AKDM4ETDP1HKDC1
SCHEMBL5080801 0.73 PTK6 (0.39) NPC1RAB9AKDM4ETDP1HKDC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NPC1 2404/4885RAB9A 2824/4885KDM4E 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.